Health Condition 1: B338- Other specified viral diseases
Conditions
Interventions
Intervention1: Loratadine 10 mg: Loratadine 10 mg once a day for 14 days
Control Intervention1: Placebo: Placebo tablets once a day for 14 days
Sponsors
Dr Arjun M C
Eligibility
Inclusion criteria
Inclusion criteria: Adults diagnosed with COVID-19 and presenting with Long COVID symptoms after 3 months of COVID-19 diagnosis (Diagnosed with RTPCR or RAT only)
Exclusion criteria
Exclusion criteria: Pregnant and lactating women Patients who are severely ill, bedridden or cannot follow up in hospital Patients having Diagnosed Liver or kidney diseases Those who do not consent
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change in the intensity of symptoms after intervention. At baseline the symptoms will be recorded using a Binary (Yes/No) symptoms grid and at follow-up the same symptoms reassessed for change (Identical, worse, better, absent). Outcome will be reported as proportion of people who experienced change in symptoms. Timepoint: All participants will be followed up for a period of 14 days from the date of enrolment. Follow-up will be done telephonically. | — |
Secondary
| Measure | Time frame |
|---|---|
| Decrease in Chalder Fatigue scale score from baseline to follow-up Timepoint: All participants will be followed up for a period of 14 days from the date of enrolment. Follow-up will be done telephonically. | — |
Countries
India
Contacts
Public ContactDr Arjun M C
St. Johns Research Institute
Outcome results
None listed